Japanese Journal of Clinical Oncology 9:261-266 (1979)
© 1979 Foundation for Promotion of Cancer Research
research-article |
Evaluation of Chemotherapy for Palliatively Resected Cases of Gastric Cancer
Department of Surgery, National Cancer Center Hospital Tokyo
Reprint requests: Kenzo Yoshikawa, M.D., Department of Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104. Japan
Received September 26, 1979; The effect of chemotherapy on palliatively resected cases of gastric cancer was evaluated on the basis of survival. The results showed a significant effect of chemotherapy only in the one-year survival rate. Drug treatment prolonged survival by at most three months. Among various regimens, the results favored significantly both the FAMT (5-FU+CPA+MMC+Chromomycin A3) combination and ftorafur alone as compared with the controls. However, there was no significant difference in survival between the group treated with the FAMT combination and that treated with ftorafur alone.
In respect to each factor for which surgery became palliative, the effect of chemotherapy was high in the cases in which the P factor (peritoneal dissemination) was dominant, i.e., those which showed clinically carcino-matous peritonitis, but there was little effect in the cases of S factor alone (serosal involvement), i.e., those which showed the status of direct extension to adjacent structures, even if only the primary lesion was removed. In terms of macroscopic or histological classification, the effect of chemotherapy was high in Borrmann's type 3 or undifferentiated type.